GR-159897 is a potent and selective
NK2receptor antagonist drug.[1] It has
anxiolytic effects in animal models,[2] and also inhibits
bronchoconstriction of the airways, which may potentially make it useful in the treatment of
asthma.[3][4]
^Beresford IJ, Sheldrick RL, Ball DI, Turpin MP, Walsh DM, Hawcock AB, et al. (January 1995). "GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors". European Journal of Pharmacology. 272 (2–3): 241–8.
doi:
10.1016/0014-2999(94)00655-q.
PMID7713168.
^Walsh DM, Stratton SC, Harvey FJ, Beresford IJ, Hagan RM (September 1995). "The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety". Psychopharmacology. 121 (2): 186–91.
doi:
10.1007/bf02245629.
PMID8545524.
S2CID7662905.
^Advenier C (July 1995). "Tachykinin NK2 receptors further characterized in the lung with nonpeptide receptor antagonists". Canadian Journal of Physiology and Pharmacology. 73 (7): 878–84.
doi:
10.1139/y95-121.
PMID8846425.
GR-159897 is a potent and selective
NK2receptor antagonist drug.[1] It has
anxiolytic effects in animal models,[2] and also inhibits
bronchoconstriction of the airways, which may potentially make it useful in the treatment of
asthma.[3][4]
^Beresford IJ, Sheldrick RL, Ball DI, Turpin MP, Walsh DM, Hawcock AB, et al. (January 1995). "GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors". European Journal of Pharmacology. 272 (2–3): 241–8.
doi:
10.1016/0014-2999(94)00655-q.
PMID7713168.
^Walsh DM, Stratton SC, Harvey FJ, Beresford IJ, Hagan RM (September 1995). "The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety". Psychopharmacology. 121 (2): 186–91.
doi:
10.1007/bf02245629.
PMID8545524.
S2CID7662905.
^Advenier C (July 1995). "Tachykinin NK2 receptors further characterized in the lung with nonpeptide receptor antagonists". Canadian Journal of Physiology and Pharmacology. 73 (7): 878–84.
doi:
10.1139/y95-121.
PMID8846425.